148 related articles for article (PubMed ID: 22983166)
1. Development of a fluorescence intensity assay for the mitotic serine/threonine protein kinase Aurora-A.
Slatter AF; Campbell S; Angell RM
J Biomol Screen; 2013 Feb; 18(2):219-25. PubMed ID: 22983166
[TBL] [Abstract][Full Text] [Related]
2. Discovery of selective aminothiazole aurora kinase inhibitors.
Andersen CB; Wan Y; Chang JW; Riggs B; Lee C; Liu Y; Sessa F; Villa F; Kwiatkowski N; Suzuki M; Nallan L; Heald R; Musacchio A; Gray NS
ACS Chem Biol; 2008 Mar; 3(3):180-92. PubMed ID: 18307303
[TBL] [Abstract][Full Text] [Related]
3. Aurora kinase inhibitors.
Kitzen JJ; de Jonge MJ; Verweij J
Crit Rev Oncol Hematol; 2010 Feb; 73(2):99-110. PubMed ID: 19369091
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with aurora kinase inhibitors: a review.
Boss DS; Beijnen JH; Schellens JH
Oncologist; 2009 Aug; 14(8):780-93. PubMed ID: 19684075
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinases: new targets for cancer therapy.
Carvajal RD; Tse A; Schwartz GK
Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
[TBL] [Abstract][Full Text] [Related]
6. Development and biological evaluation of a novel aurora A kinase inhibitor.
Sardon T; Cottin T; Xu J; Giannis A; Vernos I
Chembiochem; 2009 Feb; 10(3):464-78. PubMed ID: 19199284
[TBL] [Abstract][Full Text] [Related]
7. Is there a future for Aurora kinase inhibitors for anticancer therapy?
Carpinelli P; Moll J
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors.
Blanchard S; William AD; Lee AC; Poulsen A; Teo EL; Deng W; Tu N; Tan E; Goh KL; Ong WC; Ng CP; Goh KC; Bonday Z; Sun ET
Bioorg Med Chem Lett; 2010 Apr; 20(8):2443-7. PubMed ID: 20338758
[TBL] [Abstract][Full Text] [Related]
9. A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
Aliagas-Martin I; Burdick D; Corson L; Dotson J; Drummond J; Fields C; Huang OW; Hunsaker T; Kleinheinz T; Krueger E; Liang J; Moffat J; Phillips G; Pulk R; Rawson TE; Ultsch M; Walker L; Wiesmann C; Zhang B; Zhu BY; Cochran AG
J Med Chem; 2009 May; 52(10):3300-7. PubMed ID: 19402633
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel fluorescent probe for fluorescence correlation spectroscopic detection of kinase inhibitors.
Kawaguchi M; Terai T; Utata R; Kato M; Tsuganezawa K; Tanaka A; Kojima H; Okabe T; Nagano T
Bioorg Med Chem Lett; 2008 Jul; 18(13):3752-5. PubMed ID: 18524589
[TBL] [Abstract][Full Text] [Related]
11. Advances in Aurora kinase inhibitor patents.
Coumar MS; Cheung CH; Chang JY; Hsieh HP
Expert Opin Ther Pat; 2009 Mar; 19(3):321-56. PubMed ID: 19441907
[TBL] [Abstract][Full Text] [Related]
12. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.
Coumar MS; Tsai MT; Chu CY; Uang BJ; Lin WH; Chang CY; Chang TY; Leou JS; Teng CH; Wu JS; Fang MY; Chen CH; Hsu JT; Wu SY; Chao YS; Hsieh HP
ChemMedChem; 2010 Feb; 5(2):255-67. PubMed ID: 20039358
[TBL] [Abstract][Full Text] [Related]
13. Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase.
Yang H; Burke T; Dempsey J; Diaz B; Collins E; Toth J; Beckmann R; Ye X
FEBS Lett; 2005 Jun; 579(16):3385-91. PubMed ID: 15922328
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
[TBL] [Abstract][Full Text] [Related]
15. The dietary flavonoid luteolin inhibits Aurora B kinase activity and blocks proliferation of cancer cells.
Xie F; Lang Q; Zhou M; Zhang H; Zhang Z; Zhang Y; Wan B; Huang Q; Yu L
Eur J Pharm Sci; 2012 Aug; 46(5):388-96. PubMed ID: 22449725
[TBL] [Abstract][Full Text] [Related]
16. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
Howard S; Berdini V; Boulstridge JA; Carr MG; Cross DM; Curry J; Devine LA; Early TR; Fazal L; Gill AL; Heathcote M; Maman S; Matthews JE; McMenamin RL; Navarro EF; O'Brien MA; O'Reilly M; Rees DC; Reule M; Tisi D; Williams G; Vinković M; Wyatt PG
J Med Chem; 2009 Jan; 52(2):379-88. PubMed ID: 19143567
[TBL] [Abstract][Full Text] [Related]
17. Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity.
Coumar MS; Leou JS; Shukla P; Wu JS; Dixit AK; Lin WH; Chang CY; Lien TW; Tan UK; Chen CH; Hsu JT; Chao YS; Wu SY; Hsieh HP
J Med Chem; 2009 Feb; 52(4):1050-62. PubMed ID: 19140666
[TBL] [Abstract][Full Text] [Related]
18. Aurora kinases as anticancer drug targets.
Gautschi O; Heighway J; Mack PC; Purnell PR; Lara PN; Gandara DR
Clin Cancer Res; 2008 Mar; 14(6):1639-48. PubMed ID: 18347165
[TBL] [Abstract][Full Text] [Related]
19. Aurora kinases as targets for cancer therapy.
Mountzios G; Terpos E; Dimopoulos MA
Cancer Treat Rev; 2008 Apr; 34(2):175-82. PubMed ID: 18023292
[TBL] [Abstract][Full Text] [Related]
20. Aurora kinase inhibitors as anti-cancer therapy.
Lok W; Klein RQ; Saif MW
Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
